They compared the effect of the ASK-1 inhibitor Selonsertib (GS-4997) with that of placebo in ~1,700 patients with NASH and bridging fibrosis (F3, STELLAR-3) or compensated cirrhosis (F4, STELLAR-4) (NCT03053050 and NCT03053063). Here, MAP3K5 is linked to metabolic dysfunction-associated steatohepatitis.